The FDA’s roadmap to reduce, refine, and replace animal testing signals a transformative shift in drug development. New Approach Methodologies (NAMs) are now central to delivering safe and effective medicines ethically, while improving the predictive value of preclinical testing.

NAMs are no longer a future promise but are the standard the industry is moving toward. Evotec makes NAMs work for you by uniting advanced in vitro models, high-throughput automation and in silico prediction to deliver insights that regulators trust and innovators depend on. With over 30 years of leadership in drug discovery and development services, Evotec leverages Cyprotex and its global network of scientific excellence to help partners reduce animal testing, accelerate development timelines, and bring safer, more effective medicines to patients worldwide.

Just - Evotec Biologics' J.MD^TM suite of technologies analyse and optimize antibody candidates prior to clinical development and enable the lead selection of highly developable and manufacturable candidates.

Assessing developability and manufacturability during the selection process allows:

• Shorter timelines with lower development and manufacturing costs

• Identification of lead candidates having a better fit to existing manufacturing platforms

• Less time spent solving technical issues during process development

• Fewer liabilities which could degrade the therapeutic efficacy leading to longer shelf life and improved serum stability

Enricture is an AI-powered platform for next generation hit ID. The platform accelerates early-stage drug discovery by combining Affinity Selection-Mass Spectrometry (ASMS) with AI/ML-powered hit enrichment. This innovative approach delivers high quality hits faster and more cost effectively than traditional high throughput screening (HTS). Discover more: https://www.evotec.com/enricture

Today, Evotec’s compound management network operates across seven sites, employing approximately 140 skilled collaborators dedicated to optimizing sample workflows. This global infrastructure allows for high-throughput screening and efficient data management practices, ensuring that every aspect of compound storage and liquid handling is meticulously organized. By integrating advanced storage systems and state-of-the-art automated dispensing technologies, Evotec enhances its ability to support innovative drug discovery projects while maintaining proximity to its customers. This commitment to excellence in sample storage positions Evotec as a leader in the industry, continually driving advancements in analytical methodologies and optimization processes to accelerate the journey from compound libraries to viable drug candidates.

Evotec has been a frontrunner in hit identification and industry-standard high throughput screening for partners since 1998, resulting in extensive knowledge accumulation over a range of different modalities, target class families and cellular phenotypic signatures. Over the past 5 years, Evotec has invested over 12 million euros in its HTS and hit identification infrastructure to offer an array of state-of-the-art technologies and automated screening platforms, enabling generation of high-quality hits delivered in lightning speed. Our well-curated and high-quality compound collections of >850,000 compounds provide access to a diverse and novel biologically relevant chemical space for hit identification. Evotec has been successful in generating tractable hits for historically considered undruggable targets, thanks to our innovations in structural biology, chemistry and drug design expertise, along with technological advances.